Targeted Oncology1d
Checkpoint Inhibitors Deliver Longer OS in PPP2R1A-Mutated Endometrial Cancer vs Wild-Type Disease
Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal ...
Lixte Biotechnology provides update on progress with LB-100
LIXTE Biotechnology (LIXT) provided an update on its recent activities. Recent LIXTE Highlights Include: The first patient dosing in a Phase ...
Yahoo Finance12d
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Our colorectal trial, supported by F ... in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma. Dosing of the first ...
Morningstar12d
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer - Morningstar
Morningstar brands and products Company Portfolio ...
pharmaphorum3d
GSK confirms plan to buy cancer firm IDRx for $1bn
Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning, the UK ...